NASDAQ:REGN Regeneron Pharmaceuticals Q2 2026 Earnings Report $656.01 +4.10 (+0.63%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$657.53 +1.52 (+0.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Regeneron Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $10.21Beat/MissN/AOne Year Ago EPSN/ARegeneron Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$3.82 billionBeat/MissN/AYoY Revenue GrowthN/ARegeneron Pharmaceuticals Announcement DetailsQuarterQ2 2026Date7/30/2026TimeBefore Market OpensConference Call DateThursday, July 30, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Regeneron Pharmaceuticals Earnings HeadlinesRegeneron Q2 Earnings Preview: Not Expecting Miracles - At Least In The Short TermJuly 24 at 6:00 PM | seekingalpha.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGNJuly 24 at 12:53 PM | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 24 at 10:31 AM | globenewswire.comRegeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSSJuly 24 at 8:00 AM | prnewswire.com$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA LawJuly 24 at 6:36 AM | globenewswire.comSee More Regeneron Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Regeneron Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regeneron Pharmaceuticals and other key companies, straight to your email. Email Address About Regeneron PharmaceuticalsRegeneron Pharmaceuticals (NASDAQ:REGN) (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas. Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies. The company operates an integrated model that spans early discovery through late-stage development and commercial production, enabling it to move candidates from laboratory to market using internal capabilities as well as strategic collaborations. Key marketed products and development programs address ophthalmology, immunology, oncology and infectious disease. Regeneron’s marketed medicines include EYLEA (aflibercept) for retinal disorders and Dupixent (dupilumab), developed and co-commercialized in partnership with Sanofi, for certain inflammatory conditions. The company has also developed antibody-based therapies for oncology and infectious disease, including combination antibody treatments for COVID‑19 during the pandemic response. Regeneron serves patients in the United States and internationally through its own commercial operations and partner arrangements. Leadership includes founder and chief executive Leonard S. Schleifer and co‑founder and chief scientific officer George D. Yancopoulos, who have guided the company’s scientific strategy and commercial expansion. Regeneron continues to invest in platform technologies and a diversified pipeline aimed at advancing novel biologic therapies. View Regeneron Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off?Plugging In: How Kinder Morgan Powers Up ProfitsTSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing PowerAMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Upcoming Earnings Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
